EN DE
Watch InventionMed S.A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

InventionMed S.A (INM) fair value: what the stock is really worth

As of Oct 23, 2026: fair value (intrinsic value) of InventionMed S.A stock PLN 0.04, price PLN 0.11, upside -64.3%, quality 34 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare · PL

IS Thin data Oct 25, 2026

InventionMed S.A

INM · WAR

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 64% below what the stock costs today.

Mixed Growth (revenue 5y +260.6 %/yr in PLN)
Fair value 0.0400 PLN · Strongly overvalued (−64.3%)
Quality 34/100
Loss-making · -41.0% net margin (FY2025)
High debt
Negative free cash flow
Trails peers (1/10)
Narrow moat 5/100 · thin data
Thin data
Watch InventionMed S.A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.3325 PLN 0.0990 PLN Fair Value 0.0400 PLN Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 25, 2026.

How to read this chart

60‑month range 0.0990 PLN – 0.3325 PLN · fair‑value band 0.0300 PLN – 0.0400 PLN · the 0.1120 PLN price screens above the 0.0400 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 25, 2026.

Follow InventionMed in your weekly email

Every Wednesday you see whether InventionMed is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

InventionMed S.A. focuses on the development of medical simulators based on Virtual Realty technology for use in education in esthetic and clinical dermatology.

Show moreShow less

The company flagship project is TutorDerm, a simulator and an application that lets users perform actions necessary to treat specific dermatological diseases. It also offers double immersion, and Virtual Syringe, a training equipment for specialists in clinical and aesthetic dermatology.

In addition, the company provides education and training services, as well as simulators of medical equipment. The company was incorporated in 2012 and is based in Bydgoszcz, Poland.

Stock analysis

InventionMed S.A (INM) currently trades at 0.1120 PLN, while our model-based Fair Value estimate is 0.0400 PLN, 64.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 6 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: 0.0300 PLN (bear) to 0.0400 PLN (bull), the price of 0.1120 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

InventionMed S.A reported revenue of 3.2M PLN in FY2025 versus 10.5K PLN in FY2021, a compound +317.4%/yr. Reported net income was −1.3M PLN in FY2025.

Key figures

Market cap 38.0M PLN (≈ $9.7M) Micro · EPS (TTM) −0.0114 PLN · Net margin −41.0% · Return on equity −209% · Return on assets (EBIT) −2.5% · Free cash flow −1.1M PLN · Net debt 2.7M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 13% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −64%, INM screens richer than that median.

Fair Value models

Bear 0.0300 PLN Fair Value 0.0400 PLN Bull 0.0400 PLN
Price 0.1120 PLN · Upside -64.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA 0.0300 PLN 0.0400 PLN 0.0500 PLN 67
EV/EBIT n/a 0.0100 PLN 0.0100 PLN 63
EV/Revenue n/a n/a 0.0100 PLN 50
All 3 models by family
Multiples
EV/EBIT n/a 0.0100 PLN 0.0100 PLN 63
EV/EBITDA 0.0300 PLN 0.0400 PLN 0.0500 PLN 67
EV/Revenue n/a n/a 0.0100 PLN 50

Open the full fair value analysis →

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 97
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 0
Debt, balance sheet and risk of trouble
Investment 55
Does it invest with discipline instead of growing at any price?
Low Volatility 39
How calm the share price moves, does not count
Momentum 33
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 15
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,041.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+820.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+260.6%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10,535.2% (2020) → 8.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

INM screens overvalued: fair value 64% below the price. Compare with InBody Co →

Compare InventionMed S.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2346 stocks

Beats the sector median on 1/9 measures
Overall it trails its sector peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −64.3% · Bottom 25%
Profitability
Return on assets −3.3% · Below median
Net margin (12 months) −41.0% · Bottom 25%
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median
Balance sheet
Debt / equity 11.89× · Highest 25%

Valuation Multiplesvs Health Care median · lower = cheaper

P/B 42.98× · Priciest 25%
EV/EBITDA 7.0× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Value Added Technology Co 043150 16,990 KRW 48,636 KRW +186% vs INM
Sewoon Medical Co 100700 2,320 KRW 5,541 KRW +139% vs INM
Meta Biomed Co 059210 3,730 KRW 8,232 KRW +121% vs INM
MEKICS CO., Ltd 058110 1,437 KRW 1,581 KRW +10% vs INM
InBody Co 041830 48,250 KRW 53,075 KRW +10% vs INM
AbbVie Inc ABBV $285.64 $259.62 −9% vs INM
Roche Holding RO CHF 398.00 CHF 326.56 −18% vs INM
Johnson & Johnson, JNJ $263.81 $168.85 −36% vs INM
Eli Lilly and Company LLY $1,273 $749.40 −41% vs INM
Mediana Co 041920 9,230 KRW 5,424 KRW −41% vs INM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

InventionMed S.A · Fair Value
0.0400 PLN −64%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "InventionMed S.A Fair Value". https://www.fairvalue-calculator.com/stock/INM

Frequently asked questions

Is InventionMed S.A (INM) overvalued or undervalued?
As of Oct 25, 2026, our model estimates a fair value of 0.0400 PLN versus a price of 0.1120 PLN, about −64% upside (overvalued).
What is the fair value of INM?
Our model-based fair value for InventionMed S.A is 0.0400 PLN (as of Oct 25, 2026), built from audited fundamentals. The current price: 0.1120 PLN.
What is the quality score of INM?
InventionMed S.A has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InventionMed S.A (INM)?
Our model-based price target is the fair value of 0.0400 PLN (as of Oct 25, 2026) from 3 valuation models. Cautious scenario 0.0300 PLN, optimistic scenario 0.0400 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the InventionMed S.A stock forecast for 2026?
Our models put fair value at 0.0400 PLN, about −64% upside versus a price of 0.1120 PLN (overvalued). Cautious scenario 0.0300 PLN, optimistic scenario 0.0400 PLN. The calculation is refreshed regularly with new filings.
What is the intrinsic value of InventionMed S.A (INM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InventionMed S.A it is 0.0400 PLN per share (as of Oct 25, 2026), against a price of 0.1120 PLN. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is InventionMed S.A stock overvalued or undervalued in 2026?
As of Oct 25, 2026, INM trades above its calculated fair value: price 0.1120 PLN, fair value 0.0400 PLN, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INM?
No. The price is what the market pays today (0.1120 PLN); the fair value is what the company's own numbers justify (0.0400 PLN). For InventionMed S.A the two are 0.0720 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is InventionMed S.A worth?
The market values InventionMed S.A at about 38.0M PLN (market capitalisation, as of Oct 25, 2026). Per share that is 0.1120 PLN; our models calculate a fair value of 0.0400 PLN per share.
What do the bullish and bearish scenarios say about INM?
Our models span a range for InventionMed S.A: cautious scenario 0.0300 PLN, base 0.0400 PLN, optimistic 0.0400 PLN per share (as of Oct 25, 2026, price 0.1120 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InventionMed S.A (INM)?
Balance-sheet figures for InventionMed S.A (as of Oct 25, 2026): return on equity −209.3%, debt of 11.89 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is INM from its 52-week high?
InventionMed S.A trades at 0.1120 PLN, about 24% below its 52-week high of 0.1480 PLN and 13% above the low of 0.0990 PLN (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0400 PLN is for.
Which stocks are comparable to InventionMed S.A?
From the same area (Healthcare) we also value InBody Co, Value Added Technology Co, Mediana Co, Meta Biomed Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InventionMed S.A stock attractive at the current price?
The data as of Oct 25, 2026: price 0.1120 PLN, calculated fair value 0.0400 PLN (−64%), Quality Score 34/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INM calculated?
We run InventionMed S.A through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0400 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3 % above its aggregate fair value. InventionMed S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InventionMed S.A (INM)?
The closing price on Oct 23, 2026 was 0.1120 PLN. Our model-based fair value is 0.0400 PLN, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InventionMed S.A right now?
The price sits above even our optimistic bull case (0.0400 PLN). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of InventionMed S.A

How large is the market capitalisation of InventionMed S.A (INM)?
The market capitalisation of InventionMed S.A is 38.0M PLN (≈ $9.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of InventionMed S.A (INM)?
Earnings per share at InventionMed S.A are −0.0114 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of InventionMed S.A (INM)?
The net margin of InventionMed S.A is −41.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of InventionMed S.A (INM)?
The return on equity (ROE) of InventionMed S.A is −209% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InventionMed S.A (INM)?
On an EBIT basis the return on assets of InventionMed S.A is −2.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does InventionMed S.A (INM) generate?
The free cash flow of InventionMed S.A is −1.1M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does InventionMed S.A (INM) carry?
The net debt of InventionMed S.A is 2.7M PLN (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch InventionMed S.A in the live analysis

One click puts InventionMed S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.